Home » Insights » Post-CPhI Milan roundtable

Post-CPhI Milan roundtable

Following CPhI Milan 2026, the pharmaceutical industry is reflecting on how increasingly complex medicines are reshaping development, manufacturing and global supply. From the continued growth of biologics and advanced therapies to the practical adoption of AI, greater supply chain resilience and the push for more sustainable manufacturing, the conversations at this year’s event pointed to an industry increasingly focused on turning scientific innovation into robust, scalable and commercially viable processes. In this roundtable, Campbell Bunce, CSO at Abzena; Minjeong Seong, Director of Market Intelligence at Samsung Biologics; Martin Meeson, CEO at Axplora; and Christiane Bardroff, Chief Business Officer, Advanced Manufacturing and Development Business Unit at FUJIFILM Biotechnologies, share their perspectives on the developments shaping pharmaceutical R&D and manufacturing, and what they could mean for the industry ahead.

Campbell Bunce, Abzena

Campbell Bunce

CSO at Abzena

1. What scientific or manufacturing developments stood out most at CPhI this year, and what do they tell us about how the pharmaceutical industry is evolving?

What stood out most was the progression of the conversation from capacity to capability. Next-generation modalities, such as bispecifics, multispecifics, ADCs, AOCs are now driving the manufacturing agenda. The question has moved beyond just “can you make it?” to “can you make it reproducibly, at scale and fast enough?” We’re seeing that CDMOs are being judged on their development and innovation capability, not just on availability of capacity and scale. AI also got its own zone this year, but the key discussion was about validation and governance rather than the “promise” of what it could deliver. I was also struck that sustainability now has its own summit rather than being a side session.

Overall, this tells me the industry is maturing around complexity. Molecules are getting more complex, so the partnerships that deliver them need to be more integrated, more scientifically led and more transparent. Simply being “an alternative” provider is no longer enough. Sponsors want partners who make better scientific decisions earlier and remove the white space between development steps.

2. As biologics, cell and gene therapies continue to grow, where are the greatest scientific, manufacturing and supply-chain challenges emerging?

The biggest challenges sit where molecular complexity meets compressed timelines. Scientifically, many of the newer formats don’t behave like standard antibodies. Fusion proteins, multispecifics and conjugates with new or dual payloads need to be expressed, characterised, and potency strategies built for the molecule rather than borrowed from a platform. On the manufacturing side, the historical split between producing the antibody intermediate and doing the conjugation creates handoffs, tech-transfer risk, and delay.

In the supply chain, the pressure points are specialist materials, HPAPI handling and payload capacity, and geopolitical exposure. Many sponsors are reassessing their dependence on single regions and are actively looking at onshoring and diversification. A particular challenge is a shortage of experienced people who understand both the biology and the chemistry.

3. What will be most important in making these increasingly complex therapies scalable, reproducible and commercially viable without compromising quality or patient safety?

The most important thing is to design for manufacturability from day one. Many costly failures start in early design and CMC, such as poorly chosen conjugation chemistry or inadequate analytical characterisation, that we may be unable to fix in Phase 3. A developability-led approach asks two questions early: can we make it, and does it work? It then designs the liabilities out before they become expensive.
Second, we need platforms that perform consistently across scales. Stable pools and clones should behave the same from 50L through 2,000L, so there are no performance cliffs. Third, analytics have to lead development rather than follow it. Robust, phase-appropriate methods are what give you reproducibility and regulatory confidence. Finally, commercial-readiness thinking, covering scalable processes, analytical robustness and supply planning, now needs to happen before pivotal studies, not after them. Quality and speed aren’t a trade-off when the science is right at the start.

4. As supply chains become more complex, how can companies build greater resilience while maintaining the specialist capabilities, materials and quality standards these therapies require?

Resilience is built by reducing the number of interfaces a programme has to cross. Every handoff between providers adds risk, time and another point where materials, data or knowledge can be lost. Integrated models that combine design, cell line development, linker-payload work, conjugation, analytics, and GMP manufacture under one accountable team make the supply chain both shorter and more transparent. Geographic diversification seems to be an important factor with sponsors too – rebalancing towards Western and dual-footprint partners to reduce geopolitical exposure.

We should be careful that resilience doesn’t come at the expense of capability. Back up sourcing for specialist materials such as novel payloads, linkers and HPAPIs should be considered alongside strategic partnerships and early supply planning, and not just-in-time thinking. Just as important is direct access to experts and clear data sharing, so that when something changes, decisions are made quickly and on good science. In my view, resilience is as much about knowledge continuity as it is about where the material is sourced.

5. Where is AI beginning to deliver the most meaningful value across pharmaceutical R&D and manufacturing, and what will be needed to ensure its use is scientifically robust, validated and appropriate for regulated environments?

We see significant value from AI at the front end, in design and developability. Tools such as in silico immunogenicity and developability prediction help us triage candidates and flag liabilities before we commit expensive lab and manufacturing resources. As timelines tighten, high-throughput front-end design that can reliably predict productivity early is becoming more valuable. In manufacturing, the promise lies in predictive process control and intelligent batch records, but that is where the bar rises sharply.

To be appropriate for GXP environments, AI needs well-curated, high-quality training data, transparent models, defined intended use and proper validation, just like any other analytical method. Governance and human expert oversight remain essential. I’d also argue that AI is only as good as the experimental data that feeds it. Wet-lab biology and chemistry generating good-quality data will remain the foundation. The next step is to move AI from proof of concept into validated, production-scale workflows.

6. How can the industry make the development and manufacture of increasingly complex therapies more sustainable without compromising scientific, operational or regulatory requirements?

Sustainability can partly be addressed through reducing manufacture risk and number of failed batches. Getting the science right early, through developability, robust analytics and right-first-time process design, cuts failed runs, rework and wasted materials. That is a major and often overlooked sustainability gain. Integration helps too. Fewer tech transfers mean less duplicated method development, fewer shipments of intermediates between sites and less material spent on bridging studies. Platform approaches that perform consistently across scale reduce development cycles and the resources they consume.

Single-use systems, process intensification and smarter solvent and reagent use in conjugation chemistry all contribute, but each has to be weighed against quality and regulatory requirements. The industry is now treating sustainability as a strategic priority, as this year’s CPhI Sustainability Summit showed. The key is to build environmental measures into process design from the outset rather than retrofitting them. That way, sustainability and quality support each other.

Minjeong Seong, Samsung Biologics

Minjeong Seong

Director of Market Intelligence at Samsung Biologics

1. What scientific or manufacturing developments stood out most at CPhI this year, and what do they tell us about how the pharmaceutical industry is evolving?

At this year’s CPhI, what stood out was not a single technological breakthrough but a broader shift in how the industry defines manufacturing value. Cost and speed remain important, yet resilience, sustainability, and security of supply are becoming equally critical.

Continuous manufacturing was highlighted as a way to improve productivity and process consistency, while growing demand for GLP-1 therapies underscored the need to plan manufacturing strategies early across different dosage forms, including injectables and oral products. Likewise, the expanding ADC pipeline reinforced the importance of integrating antibody manufacturing, payload-linker supply, conjugation, and drug-product manufacturing.

Together, these developments suggest that manufacturing competitiveness can no longer be measured by capacity and cost efficiency alone. Manufacturers must respond flexibly to diverse modalities and uncertain demand while ensuring reliable supply. Ultimately, competitive advantage will depend on the ability to translate scientific innovation into robust, scalable commercial manufacturing—and sustain that performance over time.

2. As biologics as well as cell and gene therapies continue to grow, where are the greatest scientific, manufacturing, and supply-chain challenges emerging?

The greatest challenges arise where the biological complexity of these therapies meets the practical demands of manufacturing. For complex biologics, molecular heterogeneity can complicate expression, purification, and analytical characterization; in multispecific antibodies, even small differences in assembly may affect process consistency.

Cell and gene therapies face a different set of constraints. Patient-specific manufacturing, variable starting materials, and difficult potency assays make standardization harder, while viral-vector production remains technically demanding. These problems do not end at the factory gate. Many therapies depend on scarce specialized materials and resources, qualified suppliers, and tightly controlled transport, sometimes with little room for delay or substitution.

Capacity can also be difficult to access in practice when technology transfers take many months or suitable fill-finish infrastructure is limited. In my view, the issue is less a shortage of innovation than a mismatch between increasingly specialized products and the manufacturing and supply systems available to support them.

3. What will be most important in making these increasingly complex therapies scalable, reproducible, and commercially viable without compromising quality or patient safety?

Commercial readiness must be established well before commercial launch. Developers need to understand critical quality attributes, likely process constraints, and analytical requirements while a molecule is still being optimized, rather than leaving these questions until scale-up.

Established platforms can shorten development timelines, but they are not universal: complex antibodies may need tailored expression, purification, and control strategies. Modular equipment and standardized unit operations offer room to expand or transfer production without redesigning everything. Digital twins and process modelling can help test operating scenarios, provided their predictions are anchored in sound process data.

Equally important is the relationship between sponsors and manufacturing partners. Clear ownership of risks, timely exchange of technical information, and joint problem-solving make a material difference when unexpected issues arise. Reproducibility is not achieved through one technology; it comes from disciplined development and decisions that remain defensible as manufacturing moves from clinical to commercial scale.

4. As supply chains become more complex, how can companies build greater resilience while maintaining the specialist capabilities, materials, and quality standards these therapies require?

As supply chains grow more complex, pharmaceutical companies can strengthen resilience by securing manufacturing sites that can consistently meet the same quality standards. For biologics and advanced therapies, however, adding capacity is not enough. Alternative sites should be evaluated in advance for technical capability, capacity, quality systems, regulatory readiness, and technology-transfer feasibility.

Strategic partnerships with CDMOs can make this approach more practical. Beyond providing additional capacity, CDMOs can offer specialist expertise and established manufacturing infrastructure, allowing sponsors to respond to demand changes or disruptions without developing every capability in-house. Engaging manufacturing partners early also helps align process requirements, clarify responsibilities, and prepare credible contingency plans.

Geographic diversification remains valuable, particularly when regional disruptions occur, but dispersion alone does not guarantee resilience. What matters is having an alternative site that is technically qualified, operationally ready, and able to deliver consistent product quality when the primary supply route is constrained.

5. Where is AI beginning to deliver the most meaningful value across pharmaceutical R&D and manufacturing, and what will be needed to ensure its use is scientifically robust, validated, and appropriate for regulated environments?

AI is proving most useful in areas where teams must interpret more information than they can reasonably review by hand. In development, predictive models can narrow formulation or process experiments; in manufacturing, they can identify emerging trends, equipment issues, or deviations before they escalate. Reviewing large sets of batch records and historical investigations is another practical application, particularly during technology transfer.

These uses may seem less dramatic than autonomous drug discovery, but their effect on day-to-day decisions could be substantial. The challenge is making the output dependable.

Models need representative, well-governed data, clearly defined intended uses, and performance assessments under actual operating conditions. Changes to processes or data sources must trigger appropriate reassessment. In GMP environments, traceability and reviewability matter as much as prediction accuracy.

AI should help experienced people reach better-supported decisions, while responsibility for product quality and patient safety stays firmly with the people and quality systems accountable for them.

6. How can the industry make the development and manufacture of increasingly complex therapies more sustainable without compromising scientific, operational, or regulatory requirements?

Sustainability becomes more achievable when environmental improvements also make operational sense. Practical opportunities often lie within manufacturing itself: improving yields, preventing failed batches, reducing solvent and buffer consumption, and using energy more efficiently. Even the choice between single-use and stainless-steel systems should reflect a lifecycle assessment that accounts for cleaning requirements, resource consumption, and waste treatment, rather than assumptions about which option is greener.

These considerations are best introduced early in development, when materials, equipment, and process design can still be adjusted with flexibility. Once a process is established, changes can become considerably more difficult because of validation and regulatory requirements. This makes early evaluation important not only for environmental performance but also for long-term operational efficiency.
The aim is to make practical, measurable environmental improvements while protecting the fundamentals of pharmaceutical manufacturing: stable processes, reliable supply, and consistent product quality. Those priorities should remain non-negotiable throughout development and manufacturing.

Martin Meeson, Axplora

Martin Meeson

CEO at Axplora

1. What scientific or manufacturing developments stood out most at CPhI this year, and what do they tell us about how the pharmaceutical industry is evolving?

One of the key themes at CPhI was the challenge of manufacturing highly potent APIs, ADCs and GLP-1 therapies. Scientific advances in these areas are bringing exciting new medicines to patients while placing greater demands on manufacturers and their partners.

For ADCs, advances in payload and linker chemistry are expanding therapeutic possibilities. Realizing that potential requires precise synthesis, purification and bioconjugation, with close attention to how each stage affects the next.
Highly potent compounds are being targeted at an increasing array of therapeutic areas, which is great news for patients, but increases the demand for containment expertise throughout development and production.

GLP-1 therapies present a different challenge: expanding manufacturing and purification capacity while maintaining consistent quality and improving production efficiency.

Together, these developments show why capacity alone is an incomplete answer. Manufacturers must build specialist expertise, analytical capabilities and robust processes alongside their facilities. Closer collaboration with drug developers is essential to anticipate requirements and establish a reliable route from promising science to commercial supply.

2. As biologics, cell and gene therapies continue to grow, where are the greatest scientific, manufacturing and supply-chain challenges emerging?

Some of the greatest challenges are emerging where different types of molecules and manufacturing processes come together. New conjugation approaches involving oligonucleotides, peptides and steroid-based components require teams to understand how each component’s chemistry, purity and stability affect subsequent processing.

ADCs illustrate this clearly. Manufacturing the payload, linking it and attaching it to an antibody require distinct expertise, but the decisions are closely connected. An issue with one component can affect the quality, timing and availability of the finished drug substance.

The manufacturing challenge is having the right talent, equipment and analytical capabilities available at each development stage. Specialist facilities need experienced teams who can develop, transfer and scale the process safely and consistently.

The supply-chain challenge is coordinating those activities across suppliers with different lead times and capacity constraints. Early technical dialogue and visibility of development plans help partners identify dependencies, secure critical materials and prepare capabilities before they become bottlenecks. That coordination is essential to keeping increasingly complex programs moving toward patients.

3. What will be most important in making these increasingly complex therapies scalable, reproducible and commercially viable without compromising quality or patient safety?

Speed matters enormously, but customers also need confidence that we can deliver what we promise. Accelerating a development milestone has limited value if the process cannot subsequently be reproduced or supplied reliably.

Manufacturing experience therefore needs to inform development early. Teams must understand how the process will operate at scale, how quality will be controlled and what is required to handle materials safely. The customer’s likely demand and commercial requirements also need to shape those decisions.

This is where innovation has to become reliable execution. New approaches earn their value when they help a program progress with greater confidence. Scientific ambition needs the support of consistent manufacturing performance.

We should also remember why that consistency matters. It is easy to become absorbed in spreadsheets, batch records and project milestones. Ultimately, we are making medicines that can change people’s lives. Quality protects the patients who receive them, and dependable delivery helps ensure those medicines are available when needed.

4. As supply chains become more complex, how can companies build greater resilience while maintaining the specialist capabilities, materials and quality standards these therapies require?

Resilience requires access to global expertise alongside meaningful sourcing choice. Different regions bring valuable capabilities, and the industry benefits from drawing on them. Customers also need to understand their dependencies and the options available if circumstances change.

Our Axotecan program responds to customers seeking an additional European source of exatecan. Developing that option takes scientific work and a clear path through qualification and regulatory requirements. Announcing another source is only the beginning; customers need to understand its readiness and plan accordingly.

Flexibility also deserves consideration alongside cost. An arrangement that works well against today’s forecast may become restrictive if demand, clinical plans or geopolitical conditions change.

Open discussions about those possibilities help developers and manufacturers prepare together. Resilience comes from understanding where a program is exposed, building credible alternatives and retaining the ability to adapt. That requires investment informed by customer needs and relationships that remain dependable when plans change.

5. Where is AI beginning to deliver the most meaningful value across pharmaceutical R&D and manufacturing, and what will be needed to ensure its use is scientifically robust, validated and appropriate for regulated environments?

The most useful opportunities for AI are those that help scientists and engineers make better decisions. Areas such as identifying patterns in development data, informing experimental planning and investigating process variability offer clear questions against which its contribution can be tested. Claims of value need evidence of improved outcomes in the specific application.

My starting point is that technology creates value through the people using it. We need experts who understand the underlying science, can challenge an unexpected result and recognize its implications for manufacturing and patients.

For regulated use, that means defining the tool’s purpose, establishing the reliability of its data and demonstrating that its performance is appropriate to the decision it supports. Validation, traceability and human accountability must reflect that intended use.

AI should face the same test as other innovations: does it help us develop and manufacture medicines more effectively and reliably? The strength of the evidence matters more than the novelty of the technology.

6. How can the industry make the development and manufacture of increasingly complex therapies more sustainable without compromising scientific, operational or regulatory requirements?

The opportunity is to build sustainability into everyday development and manufacturing decisions. That means understanding where energy, materials and water are being consumed, then identifying improvements whose benefits we can measure.

Practical measures include improving yields, recovering solvents and heat, recycling water and making heating, cooling and air-handling systems more efficient. These supporting systems deserve attention alongside the chemistry itself.

AI can help teams interpret process and utility data, identify patterns of avoidable consumption and prioritize opportunities for investigation. Like all new technology, its value should be judged by demonstrated resource savings, supported by reliable data and scientific expertise.

The discipline of implementation matters. Establish a baseline, test the proposed improvement and measure its performance afterward. Any change must undergo appropriate risk assessment, qualification, validation and change control. Containment, product quality and patient safety remain fundamental requirements.

Earlier collaboration with customers creates more scope to consider environmental performance during development, while suppliers are essential to addressing emissions across the value chain. The priority is turning commitments into practical improvements that remain effective throughout a product’s commercial life.

Christiane Bardroff, FUJIFILM Biotechnologies

Christiane Bardroff

Chief Business Officer, Advanced Manufacturing and Development Business Unit, at FUJIFILM Biotechnologies

1. What scientific or manufacturing developments stood out most at CPHI this year, and what do they tell us about how the pharmaceutical industry is evolving?

At CPhI this year, the topic of AI has moved from hype to progress, with data inputs, anecdotal commentary and case studies, all suggesting that the integration of AI in drug discovery and development will significantly widen the pipeline. Moreover, advancements in silico modeling will increase success rates and the probability of commercialization for new therapeutics.

While AI is rapidly advancing drug discovery and development, our industry needs to be prepared for AI to also provide precision and speed gains in manufacturing so that manufacturing does not become the constraint in the lifecycle of a drug.

2. As biologics, cell and gene therapies continue to grow, where are the greatest scientific, manufacturing and supply-chain challenges emerging?

As pipelines become increasingly complex, there is tremendous value in closer coordination between development and manufacturing, especially when it comes to complex modalities. For example, a cell line may perform well small-scale but require significant redesign when demand changes or when the process moves from small-scale to large-scale. These variables can affect development, comparability, process characterization and validation.

The companies that succeed are the ones that build manufacturing into development from day one and mitigate risk by aligning innovative technologies and regulatory expectations within a broad, unified manufacturing and supply strategy.

From a manufacturing and supply chain perspective, the industry is operating in a very different environment than it was even a few years ago, when manufacturers prioritized production in the lowest-cost location.

Now, companies are navigating supply chain volatility, geopolitical uncertainty and evolving regulatory expectations, all while continuing to accelerate speed to market and minimize costs.

Our partners today are prioritizing local-for-local manufacturing, producing close to patients to navigate these challenges.

3. What will be most important in making these increasingly complex therapies scalable, reproducible and commercially viable without compromising quality or patient safety?

At FUJIFILM Biotechnologies, our answer to this is our kojoX approach. KojoX harmonizes processes, procedures, systems, data, facility designs and equipment across our global manufacturing network to increase speed while ensuring consistency, quality, scalability and supply chain resilience.

kojoX is about creating a more connected manufacturing network, operating under unified quality management and following best practices to ensure consistent product quality and regulatory compliance, with a harmonious way of working that regulators can recognize.

This model gives customers greater optionality; programs can scale up, scale out or establish supply in another region with less re-engineering and lower technology-transfer risk.

4. As supply chains become more complex, how can companies build greater resilience while maintaining the specialist capabilities, materials and quality standards these therapies require?

Building supply-chain resilience starts with partnership and bringing in manufacturing expertise at the development and design stage. Early consideration of process design, scalability, technology alignment and global supply strategy helps companies plan for changing demand while keeping quality and patient safety central to those decisions.

Choosing a long-term CDMO partner with modality-specific expertise helps preserve the specialist capabilities that these therapies require. This includes highly trained staff, robust GMP quality systems, regulatory experience and reliable supply.

Our kojoX approach supports this through standardization. Aligning equipment, processes, quality systems and ways of working reduce the need to redesign a process each time it moves between facilities. This can make technology transfer faster and more predictable while maintaining quality standards at all manufacturing locations.

5. Where is AI beginning to deliver the most meaningful value across pharmaceutical R&D and manufacturing, and what will be needed to ensure its use is scientifically robust, validated and appropriate for regulated environments?

AI is most valuable when it strengthens decision-making and execution, rather than a standalone IT solution. An example of these benefits in our industry is helping to make technology transfer more consistent, predictive maintenance – helping identify equipment issues before they disrupt production – and in silico experimentation – that reduces wet-lab-tests and is therefore more cost efficient and much faster.

However, AI is only as effective as the foundation behind it. An algorithm cannot compensate for fragmented systems, inconsistent data or weak operational discipline. A strong data foundation and standards must already be in place for AI to be effective.

Trusted by

40 years connecting the world of science for industry

Our journals:

Login